Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07501702 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis

Study acronym: ETNA
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 27 to 28v10
  2. Study sites: 26 to 27 Eligibility criteria expanded, about 6 wordsv9 Show 1 more changeShow less
    • Eligibility criteria expanded, about 6 words

    See this version in full on ClinicalTrials.gov ↗

  3. Study sites: 24 to 26v8
  4. Trial sites expanded: 17 → 24 locationsv7
  5. Trial sites expanded: 11 → 17 locationsv6
  6. Study sites: 9 to 11 Start date changed from estimate of May 2026 to May 13, 2026v5 Show 1 more changeShow less
    • Start date changed from estimate of May 2026 to May 13, 2026
  7. Trial sites expanded: 6 → 9 locations Start date: Apr 16, 2026 to May 2026v4 Show 1 more changeShow less
    • Start date: Apr 16, 2026 to May 2026
  8. Trial sites expanded: 3 → 6 locationsv3
  9. Recruitment opened Trial sites expanded: 0 → 3 locationsv2 Show 1 more changeShow less
    • Trial sites expanded: 0 → 3 locations
  10. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to evaluate the pharmacodynamic (PD) effect, safety, and tolerability of Povetacicept in participants with generalized myasthenia gravis (gMG).
Trial Details
NCT Number NCT07501702
Lead Sponsor Vertex Pharmaceuticals Incorporated
Conditions Myasthenia Gravis, Generalized
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov